Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies - PubMed (original) (raw)

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies

S Laal et al. J Virol. 1994 Jun.

Abstract

The ability of antibodies to the V3 region and the CD4-binding domain (CD4bd) of human immunodeficiency virus type 1 (HIV-1) to act in synergy to neutralize HIV has been demonstrated previously. However, synergy between antibodies to other HIV-1 epitopes has not been studied. We have used 21 combinations of human monoclonal antibodies (MAbs) directed against different epitopes of the gp120 and gp41 proteins of HIV-1 to evaluate their ability to act in synergy to neutralize HIV-1. Combinations of anti-V3 and anti-CD4bd antibodies, anti-V3 and anti-gp120 C-terminus antibodies, anti-CD4bd and anti-C-terminus antibodies, anti-V3 and anti-gp41 antibodies, and anti-CD4bd and anti-gp41 antibodies were tested. Our results show that some, but not all anti-V3 antibodies can act in synergy with anti-CD4bd antibodies. In addition, for the first time, antibodies to the C-terminus region have been found to act in synergy with the anti-CD4bd antibodies. Various anti-CD4bd MAbs also act in synergy when used together. The use of such cocktails of human MAbs for passive immunization against HIV-1 may prove to be important for therapy in postexposure settings and for prevention of maternal-fetal transmission of the virus. The results also provide information on the types of antibodies that should be elicited by an effective vaccine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. AIDS Res Hum Retroviruses. 1987 Fall;3(3):283-302 - PubMed
    1. J Gen Virol. 1987 Jul;68 ( Pt 7):2007-12 - PubMed
    1. Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 - PubMed
    1. Virology. 1988 Jun;164(2):362-72 - PubMed
    1. Nature. 1991 Aug 1;352(6334):436-8 - PubMed

MeSH terms

Substances

LinkOut - more resources